Literature DB >> 18395493

Conventional myomectomy.

Neelanjana Mukhopadhaya1, Chaminda De Silva, Isaac T Manyonda.   

Abstract

In addition to the conventional/older treatments of myomectomy and hysterectomy, the options now available to the woman with symptomatic fibroids, especially if she wishes to conserve her uterus, include medical treatments such as mifepristone, minimally invasive therapies such as uterine artery embolization (UAE) or magnetic-resonance-guided focused ultrasound surgery (MRgFUS), and laparoscopic or vaginal myomectomy. It is generally accepted, and with justification, that conventional myomectomy is associated with significant morbidity, especially excessive peri-operative blood loss, recurrence of the fibroids and adhesion formation, which might compromise the very reason, i.e. fertility, which the operation is performed to preserve. However, the newer treatments have significant limitations: medical treatments are promising but, to date, have been found to be of limited efficacy; UAE is still under evaluation and its impact on fertility has yet to be researched; and MRgFUS is an even newer therapy which is limited to centres with high technology and hugely expensive open magnetic resonance imaging facilities. Both UAE and MRgFUS cause shrinkage rather than removal of the fibroids, and have limited efficacy when used with really large, multiple fibroids. Laparoscopic myomectomy is also limited by the size and number of fibroids that can be treated by this approach, and demands laparoscopic skills that are still lacking in most institutions; limitations which also apply to vaginal myomectomy. It is therefore evident that conventional abdominal myomectomy still has a major role to play. There are no limitations on size and number of fibroids, and there are good data showing improvement in outcomes of assisted reproduction treatments following myomectomy. The widespread fallacy is probably the assumption that any gynaecological surgeon can perform a myomectomy; good conventional myomectomy demands no less skill than the laparoscopic approach. There is a need to continue to refine and innovate, especially with regard to reducing blood loss during surgery, reducing the risk of adhesion formation, reducing the risk of recurrence, and reconstruction of uteri to approximate anatomical normality and physiological integrity so that they can carry a pregnancy without complications such as scar rupture. This chapter will review the position of conventional myomectomy and describe approaches to optimizing outcomes following myomectomy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18395493     DOI: 10.1016/j.bpobgyn.2008.01.012

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  10 in total

Review 1.  GnRH agonists: do they have a place in the modern management of fibroid disease?

Authors:  Vikram Sinai Talaulikar; Anna-Maria Belli; Isaac Manyonda
Journal:  J Obstet Gynaecol India       Date:  2012-09-27

2.  Refusal of blood transfusion by Jehovah's Witness women: a survey of current management in obstetric and gynaecological practice in the U.K.

Authors:  Sahana Gupta; Joseph Onwude; Roberto Stasi; Isaac Manyonda
Journal:  Blood Transfus       Date:  2012-07-04       Impact factor: 3.443

Review 3.  Uterine fibroids and current clinical challenges.

Authors:  Salama S Salama; Gökhan S Kılıç
Journal:  J Turk Ger Gynecol Assoc       Date:  2013-03-01

4.  Fertility and Pregnancy Outcome after Myoma Enucleation by Minilaparotomy under Microsurgical Conditions in Pronounced Uterus Myomatosus.

Authors:  K Floss; G-J Garcia-Rocha; S Kundu; C S von Kaisenberg; P Hillemanns; C Schippert
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-01       Impact factor: 2.915

5.  Clostridium hathewayi bacteraemia and surgical site infection after uterine myomectomy.

Authors:  Ala S Dababneh; Avish Nagpal; Bharath Raj Varatharaj Palraj; M Rizwan Sohail
Journal:  BMJ Case Rep       Date:  2014-03-04

6.  Pregnancy after complex myomectomy: neither age of patient nor size, number or location of fibroids should be a barrier.

Authors:  Vikram Sinai Talaulikar; Sahana Gupta; Isaac Manyonda
Journal:  JRSM Short Rep       Date:  2012-03-26

7.  Postoperative Quality of Life and Sexual Function in Premenopausal Women Undergoing Laparoscopic Myomectomy for Symptomatic Fibroids: A Prospective Observational Cohort Study.

Authors:  Julia Caroline Radosa; Christoph Georg Radosa; Russalina Mavrova; Stefan Wagenpfeil; Amr Hamza; Ralf Joukhadar; Sascha Baum; Maria Karsten; Ingolf Juhasz-Boess; Erich-Franz Solomayer; Marc Philipp Radosa
Journal:  PLoS One       Date:  2016-11-29       Impact factor: 3.240

Review 8.  Robot-assisted laparoscopic myomectomy: current status.

Authors:  Sara E Arian; Jessian L Munoz; Suejin Kim; Tommaso Falcone
Journal:  Robot Surg       Date:  2017-01-23

9.  Robot-Assisted Laparoscopic Myomectomy versus Abdominal Myomectomy for Large Myomas Sized over 10 cm or Weighing 250 g.

Authors:  Sa Ra Lee; Eun Sil Lee; Young Jae Lee; Shin Wha Lee; Jeong Yeol Park; Dae Yeon Kim; Sung Hoon Kim; Yong Man Kim; Dae Shik Suh; Young Tak Kim
Journal:  Yonsei Med J       Date:  2020-12       Impact factor: 2.759

10.  Pressure-Induced Fibroid Ischemia: First-In-Human Experience with a Novel Device for Laparoscopic Treatment of Symptomatic Uterine Fibroids.

Authors:  Michael G Tal; Ran Keidar; Gilad Magnazi; Ohad Henn; Jin Hee Kim; Scott G Chudnoff; Kevin J Stepp
Journal:  Reprod Sci       Date:  2022-08-08       Impact factor: 2.924

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.